1Geyer CE,Forster J,Lindquist D,et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer[J]. N Engl J Med, 2006,355(26): 2733-2743.
2Nahta R, Yuan LX, Du Y, et al. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells :effects on insulinlike growth factor I signaling[J].Mol Cancer Ther, 2007,6 (2) : 667-674.
3Xia W, Mullin RJ,Keith BR,et al. Anti-tumor activity of GW572016,a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erkl/2 and Akt path ways[J].Oncogene, 2002,21(41) : 6255-6263.
4Spector NL, Xia W , Burris H, et al. Study of the biologic effects of lapatinib,a reversible inhibitor of ErbBl and ErbB2 tyrosine kinases,on tumor growth and survival pathways in patients with advanced malignancies[J]. J Clin Oncol, 2005,23(11) : 2502-2512.
5Nelson MH,Dolder CR. Lapatinib:a novel dual tyrosine kinase inhibitor with activity in solid tumors[J].Ann Pharmacother, 2006,40(2) : 261-269.
6Saez R, Molina MA, Ramsey EE, et al. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer[J]. Clin Cancer Res,2006,12(2):424-431.
7Konecny GE,Pegram MD,Venkatesan N,et al.Activity of the dual kinase inhibitor lapatinib (GW572016) against Her-2 overexpressing and trastuzumab treated breast cancer cells[J].Cancer Res, 2006,66(3) : 1630-1639.
8Zhou Y, Li S, Hu YP, et al. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinima GEO cells to apoptosis[J].Cancer Res , 2006,66(1):404-411.
9McHugh LA,Kri-ajevska M,Mellon JK,et al. Combined treatment of bladder cancer cell line with lapatinib and varying chemotherapy regimens-evidence of schedule-dependent synergy[J].Urology, 2007,69(2):390-394.
10Ito Y,Tokudome N,Sugihara T,et al.Dose Lapatinib,a small-molecule tyrosine kinase inhabitor,constitute a breakthrough in the treatment of breast cancer[J].Breast Cancer, 2007,14(2): 156-162.
